Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
Reanalysis of clinical exome data at a two- to three-year interval could result in an incremental 10 percent diagnostic yield…
From - Diagnostic Testing & Emerging Technologies
Patients increasingly prefer to receive laboratory test results via password-protected websites and portals, according to…
From - Diagnostic Testing & Emerging Technologies
Despite appealing the Centers for Medicare and Medicaid's (CMS) sanctions resulting from inspection of…